Home - Invivoscribe

Invivoscribe-Shop-Product-Availability-Key-1920×160-Image-2x-001

Invivoscribe-Shop-Product-Availability-Key-Image-2x-002

All Products

Cat #: 91210009
LymphoTrack^® Dx IGH FR1 Assay Kit A – MiSeq®
The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...
View Product
Cat #: 91210039
LymphoTrack^® Dx IGH FR1 Assay Panel – MiSeq^®
The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...
View Product
Cat #: 91210129
LymphoTrack^® Dx IGH FR1/2/3 Assay Kit A – MiSeq
The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...
View Product
Cat #: 91210139
LymphoTrack^® Dx IGH FR1/2/3 Assay Panel – MiSeq
The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...
View Product
Cat #: 91210089
LymphoTrack^® Dx IGH FR2 Assay Kit A – MiSeq
The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...
View Product
Cat #: 91210099
LymphoTrack^® Dx IGH FR2 Assay Panel – MiSeq
The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...
View Product
Cat #: 91210109
LymphoTrack^® Dx IGH FR3 Assay Kit A – MiSeq^®
The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...
View Product
Cat #: 91210119
LymphoTrack^® Dx IGH FR3 Assay Panel – MiSeq^®
The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...
View Product
Cat #: 91210059
LymphoTrack^® Dx IGHV Leader Somatic Hypermutation Assay Kit A – MiSeq®
The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...
View Product
Cat #: 91210069
LymphoTrack^® Dx IGHV Leader Somatic Hypermutation Assay Panel – MiSeq®
The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segmen...
View Product
Cat #: 91220009
LymphoTrack^® Dx IGK Assay Kit A – MiSeq^®
This LymphoTrack® Dx IGK Assay – MiSeq® represents a significant improvement over existing clonality assays using fragment analysis, as it efficie...
View Product
Cat #: 91220019
LymphoTrack^® Dx IGK Assay Panel – MiSeq®
This LymphoTrack® Dx IGK Assay – MiSeq® represents a significant improvement over existing clonality assays using fragment analysis, as it effic...
View Product
Cat #: 92250009
LymphoTrack^® Dx TRB Assay Kit A – MiSeq®
This LymphoTrack TRB Assay – MiSeq® represents a significant improvement over existing clonality assays using fragment analysis as it efficientl...
View Product
Cat #: 92250019
LymphoTrack^® Dx TRB Assay Panel – MiSeq®
This LymphoTrack TRB Assay – MiSeq® represents a significant improvement over existing clonality assays using fragment analysis as it efficientl...
View Product
Cat #: 92270019
LymphoTrack^® Dx TRG Assay Kit A – MiSeq^®
The LymphoTrack® Dx TRG Assay for the Illumina® MiSeq® is an in vitro diagnostic product intended for next-generation sequencing (NGS) based determ...
View Product
Cat #: 92270009
LymphoTrack^® Dx TRG Assay Panel – MiSeq^®
The LymphoTrack® Dx TRG Assay for the Illumina MiSeq® is an in vitro diagnostic product intended for next-generation sequencing (NGS) based determin...
View Product
Cat #: 95000009
LymphoTrack^® Dx Software – MiSeq^®
The LymphoTrack® Dx Assays were designed to produce sequencing data that can be analyzed using the LymphoTrack Dx Software – MiSeq® package pr...
View Product

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

October 30th, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Territory

Detection

Regulatory Classification

Locus Target

Application

Product Type

Box Type

Design

Size

All Products

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

October 30th, 2020 Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Territory

Detection

Regulatory Classification

Locus Target

Application

Product Type

Box Type

Design

Size

All Products

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

October 30th, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma